Literature DB >> 25747925

Pharmacotherapy for alcohol use disorder: current and emerging therapies.

Robert M Swift1, Elizabeth R Aston.   

Abstract

Alcohol use disorder is a heterogeneous illness with a complex biology that is controlled by many genes and gene-by-environment interactions. Several efficacious, evidence-based treatments currently exist for treating and managing alcohol use disorder, including a number of pharmacotherapies that target specific aspects of biology that initiate and maintain dangerous alcohol misuse. This article reviews the neurobiological and neurobehavioral foundation of alcohol use disorder, the mechanisms of action and evidence for the efficacy of currently approved medications for treatment, and the literature on other emerging pharmacotherapies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25747925      PMCID: PMC4790835          DOI: 10.1097/HRP.0000000000000079

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  140 in total

Review 1.  Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders.

Authors:  William R Miller; Paula L Wilbourne
Journal:  Addiction       Date:  2002-03       Impact factor: 6.526

2.  A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.

Authors:  Antoni Gual; Yuan He; Lars Torup; Wim van den Brink; Karl Mann
Journal:  Eur Neuropsychopharmacol       Date:  2013-04-03       Impact factor: 4.600

3.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

4.  The association of the appetitive peptide acetylated ghrelin with alcohol craving in early abstinent alcohol dependent individuals.

Authors:  Anne Koopmann; Christoph von der Goltz; Martin Grosshans; Christina Dinter; Meike Vitale; Klaus Wiedemann; Falk Kiefer
Journal:  Psychoneuroendocrinology       Date:  2011-12-14       Impact factor: 4.905

5.  Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers.

Authors:  David Ted George; David W Herion; Cheryl L Jones; Monte J Phillips; Jacqueline Hersh; Debra Hill; Markus Heilig; Vijay A Ramchandani; Christopher Geyer; David E Spero; Erick D Singley; Stephanie S O'Malley; Raafat Bishai; Robert R Rawlings; George Kunos
Journal:  Psychopharmacology (Berl)       Date:  2009-11-10       Impact factor: 4.530

6.  Disulfiram treatment of alcoholism. A Veterans Administration cooperative study.

Authors:  R K Fuller; L Branchey; D R Brightwell; R M Derman; C D Emrick; F L Iber; K E James; R B Lacoursiere; K K Lee; I Lowenstam
Journal:  JAMA       Date:  1986-09-19       Impact factor: 56.272

7.  Gabapentin treatment for alcohol dependence: a randomized clinical trial.

Authors:  Barbara J Mason; Susan Quello; Vivian Goodell; Farhad Shadan; Mark Kyle; Adnan Begovic
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

Review 8.  A role for brain stress systems in addiction.

Authors:  George F Koob
Journal:  Neuron       Date:  2008-07-10       Impact factor: 17.173

9.  A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.

Authors:  B J Mason; E C Ritvo; R O Morgan; F R Salvato; G Goldberg; B Welch; E Mantero-Atienza
Journal:  Alcohol Clin Exp Res       Date:  1994-10       Impact factor: 3.455

10.  The incentive salience of alcohol: translating the effects of genetic variant in CNR1.

Authors:  Kent E Hutchison; Heather Haughey; Michelle Niculescu; Joe Schacht; Alan Kaiser; Jerry Stitzel; William J Horton; Francesca Filbey
Journal:  Arch Gen Psychiatry       Date:  2008-07
View more
  17 in total

1.  Hazardous Alcohol Use Associated with Increased Sexual Risk Behaviors Among People Who Inject Drugs.

Authors:  Nadia Fairbairn; Kanna Hayashi; M-J Milloy; Seonaid Nolan; Paul Nguyen; Evan Wood; Thomas Kerr
Journal:  Alcohol Clin Exp Res       Date:  2016-09-17       Impact factor: 3.455

2.  Cortisol as a Biomarker of Alcohol Use in Combat Veterans: A Literature Review and Framework for Future Research.

Authors:  Yvette Z Szabo; Tessa Breeding; Christina Hejl; Rakeshwar S Guleria; Steven M Nelson; Laura Zambrano-Vazquez
Journal:  J Dual Diagn       Date:  2020-06-04

3.  NOP Receptor Antagonists Decrease Alcohol Drinking in the Dark in C57BL/6J Mice.

Authors:  Gloria Brunori; Michelle Weger; Jennifer Schoch; Katarzyna Targowska-Duda; Megan Barnes; Anna Maria Borruto; Linda M Rorick-Kehn; Nurulain T Zaveri; John E Pintar; Roberto Ciccocioppo; Lawrence Toll; Andrea Cippitelli
Journal:  Alcohol Clin Exp Res       Date:  2019-08-21       Impact factor: 3.455

4.  Mifepristone Decreases Chronic Voluntary Ethanol Consumption in Rhesus Macaques.

Authors:  Vanessa A Jimenez; Nicole A R Walter; Tatiana A Shnitko; Natali Newman; Kaya Diem; Lauren Vanderhooft; Hazel Hunt; Kathleen A Grant
Journal:  J Pharmacol Exp Ther       Date:  2020-09-01       Impact factor: 4.030

5.  On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications.

Authors:  Steven J Nieto; Erica N Grodin; Lara A Ray
Journal:  Expert Rev Precis Med Drug Dev       Date:  2020-02-10

Review 6.  Naltrexone Initiation in the Inpatient Setting for Alcohol Use Disorder: A Systematic Review of Clinical Outcomes.

Authors:  Robert W Kirchoff; Norhan M Mohammed; Jack McHugh; Matej Markota; Thomas Kingsley; Jonathan Leung; M Caroline Burton; Rahul Chaudhary
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-04-08

7.  FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit.

Authors:  Kyle H Flippo; Samuel A J Trammell; Matthew P Gillum; Iltan Aklan; Misty B Perez; Yavuz Yavuz; Nicholas K Smith; Sharon O Jensen-Cody; Bolu Zhou; Kristin E Claflin; Amy Beierschmitt; Anders Fink-Jensen; Filip K Knop; Roberta M Palmour; Brad A Grueter; Deniz Atasoy; Matthew J Potthoff
Journal:  Cell Metab       Date:  2022-02-01       Impact factor: 31.373

Review 8.  Intranasal Insulin: a Treatment Strategy for Addiction.

Authors:  Bhavani Kashyap; Leah R Hanson; William H Frey Ii
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

Review 9.  Cognitive-Affective Transdiagnostic Factors Associated With Vulnerability to Alcohol and Prescription Opioid Use in the Context of Pain.

Authors:  Emily L Zale; Jessica M Powers; Joseph W Ditre
Journal:  Alcohol Res       Date:  2021-07-15

Review 10.  Immune treatments for alcohol use disorder: A translational framework.

Authors:  Lindsay R Meredith; Elizabeth M Burnette; Erica N Grodin; Michael R Irwin; Lara A Ray
Journal:  Brain Behav Immun       Date:  2021-07-31       Impact factor: 19.227

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.